Skip to main content
SpringerLink
Log in

Decade in review—dyslipidaemia

Resurgence of targets and compounds to treat dyslipidaemia

  • News & Views
  • Published:

From Nature Reviews Cardiology

View current issue Sign up to alerts

Over the past decade, we have witnessed the unparalleled success of statins to treat dyslipidaemia. Target identification by Mendelian randomization, human monoclonal antibodies, gene therapy, RNA-based targets, and atherogenic lipoproteins other than LDL cholesterol have fuelled intense development efforts that might bear fruit in the very near future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: LDL-cholesterol levels achieved by lipid-lowering therapies developed during the past 3 decades in patients with familial hypercholesterolaemia.

References

  1. Cannon, C. P. et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350, 1495–1504 (2004).

    Article  CAS  Google Scholar 

  2. LaRosa, J. C. et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 352, 1425–1435 (2005).

    Article  CAS  Google Scholar 

  3. Ridker, P. M. et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359, 2195–2207 (2008).

    Article  CAS  Google Scholar 

  4. Kastelein, J. J. P. et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 114, 1729–1735 (2006).

    Article  CAS  Google Scholar 

  5. Stroes, E. S. et al. Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler. Thromb. Vasc. Biol. 28, 2303–2304 (2008).

    Article  CAS  Google Scholar 

  6. Kamstrup, P. R., Tybjærg-Hansen, A., Steffensen, R. & Nordestgaard, B. G. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 301, 2331–2339 (2009).

    Article  CAS  Google Scholar 

  7. Do, R. et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat. Genet. 45, 1345–1352 (2013).

    Article  CAS  Google Scholar 

  8. Stein, E. A. et al. Effect of a monoclonal antibodies to PCSK9 on LDL cholesterol. N. Engl. J. Med. 366, 1108–1118 (2012).

    Article  CAS  Google Scholar 

  9. Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G. & Tybjærg-Hansen, A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N. Engl. J. Med. 371, 32–41 (2014).

    Article  Google Scholar 

  10. The TG and HDL Group of the Exome Sequencing Project, National, Heart, Lung, and Blood Institute. Loss-of-function mutations in APOC3, triglycerides, and coronary heart disease. N. Engl. J. Med. 371, 22–31 (2014).

Download references

Author information

Authors and Affiliations

  1. Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, Amsterdam, 1105 AZ, Netherlands

    John J. P. Kastelein

Authors
  1. John J. P. Kastelein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John J. P. Kastelein.

Ethics declarations

Competing interests

J.J.P.K. declares that he has acted as a consultant and received honouraria from the following companies: Aegerion, Amgen, AstraZeneca, Atheronova, Boehringer Ingelheim, Catabasis, Cerenis, CSL Behring, Dezima Pharmaceuticals, Eli Lilly, Esperion, Genzyme, Isis, Merck, Novartis, Omthera, Pronova, Regeneron, Sanofi, The Medicines Company, UniQure, and Vascular Biogenics.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kastelein, J. Resurgence of targets and compounds to treat dyslipidaemia. Nat Rev Cardiol 11, 629–631 (2014). https://doi.org/10.1038/nrcardio.2014.132

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrcardio.2014.132

  • Springer Nature Limited

This article is cited by

Search

Navigation